Image source: Getty Images.
A savvy decision by Tesaro (NASDAQ: TSRO) to buy the rights to a novel anti-tumor drug from Merck & Co. (NYSE: MRK) for $7 million up front in 2012 has just paid off big for patients and Tesaro investors.
Image source: Getty Images.
A savvy decision by Tesaro (NASDAQ: TSRO) to buy the rights to a novel anti-tumor drug from Merck & Co. (NYSE: MRK) for $7 million up front in 2012 has just paid off big for patients and Tesaro investors.